Diagnosis and Treatment of Minor Ischaemic Stroke According to the Etiology and Pathogenesis

NCT ID: NCT01665729

Last Updated: 2012-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Negligence or contempt of the etiology and pathogenesis of minor ischaemic stroke in the early diagnosis and effective treatment leads to more than 40-50% of patient with recurrent episodes, and 10% patient died. Therefore, diagnosis and treatment of minor ischaemic stroke according to the etiology and pathogenesis is important.

The 2007 Korean modified TOAST type got some progress, but there exists two major disadvantages: imperfect diagnosis and pathogenesis of perforator artery infarction etiology; lack of typing according to the pathogenesis of large atherosclerotic infarction and taking measures of treatment according to the new types. Recently, domestic professor Gaoshan proposes new approach to diagnose and treat minor ischaemic stroke according to the etiology and pathogenesis of CISS typing, but the pathogenesis of hypoperfusion infarction with severe stenosis of large artery is unclear. Is it low perfusion? Or artery-artery embolization? Or both? How to distinguish the pathogenesis of branch artery disease: by atherosclerosis? Or hyalinosis? Or both? How to check the validity of clinical types? This study take different interventions according to different types and observation of the long term clinical results of intervention( mortality, recurrence rate, disability rate and rate of cerebral hemorrhage and subarachnoid hemorrhage), in order to clarify the new types can indeed solve the current problem of minor ischaemic stroke with high mortality, recurrence rate, disability rate and rate of cerebral hemorrhage and subarachnoid hemorrhage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischaemic Stroke

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

etiology pathogenesis minor ischaemic stroke types intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

artery-artery embolus

There is no hypoperfusion ( contralateral compensatory is good )

No interventions assigned to this group

Hypoperfusion

Contralateral compensatory not sufficient

No interventions assigned to this group

Hypoperfusion and embolus amotic

Hypoperfusion and embolus amotic

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

one of two conditions:

1. conscious patients with any of NIHSS score = 1,or
2. NIHSS ≤ 3

Exclusion Criteria

* patients Over 80 years of age
* patients With serious heart, lung, liver, kidney dysfunction or
* severe systemic complications,
* a known tumor,
* pregnancy,
* having a history of cerebral hemorrhage
Minimum Eligible Age

20 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Li Haiyan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Li Haiyan

Dr.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhengqi Lu, prof.

Role: STUDY_CHAIR

Department of Neurology,The Third Affiliated Hospital of Sun yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Neurology,The Third Affiliated Hospital of Sun yat-sen University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhengqi Lu, prof.

Role: CONTACT

Phone: 86 13570102668

Email: [email protected]

Haiyan Li, Dr.

Role: CONTACT

Phone: 86 15920474159

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhengqi Lu, prof.

Role: primary

Haiyan Li

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-2-48

Identifier Type: -

Identifier Source: org_study_id